⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
BIOA News
BioAge Labs, Inc. Common Stock
The Nomination Committee's proposal for the election of Board members and Chairperson of the Board in BioArctic AB USA - English USA - English
prnewswire.com
BIOA
Form 8-K
sec.gov
BIOA
New data on long-term, real-world treatment with lecanemab presented at the 2026 AD/PD™ congress
prnewswire.com
BIOA
BIIB
BioAge Labs to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
globenewswire.com
BIOA
BLA for subcutaneous formulation of Leqembi® designated for Priority Review in China USA - English USA - English
prnewswire.com
BIOA
BIIB
BLA for subcutaneous formulation of Leqembi® designated for Priority Review in China USA - English USA - English
prnewswire.com
BIOA
BIIB
BioAge Announces Pricing of Upsized $115.0 Million Public Offering
globenewswire.com
BIOA
BioAge Announces Proposed Public Offering
globenewswire.com
BIOA
BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026
globenewswire.com
BIOA
BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with Elevated Cardiovascular Risk
globenewswire.com
BIOA